



Press Release

Poxel 1Q15 Cash and Turnover

Lyon, France, May 5, 2015 -POXEL (Euronext – POXEL - FR0012432516), an independent French biopharmaceutical company focused on the development of drugs to treat type 2 diabetes, announces today its cash position and its turnover for the first quarter 2015.

As of March 31st, 2015, the cash and cash equivalents amounted to €33.0 million* including the gross proceeds from the Company's successful IPO in February 2015 raising €26.8 million.

As expected, Poxel did not generate revenues during the first quarter 2015.

These figures are consistent with the expectations of the Company and its growth strategy which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.

*unaudited

Next financial press release: 1H15 turnover & cash position on 15 July, 2015

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development.

Contacts

Investor relations / Media - France

NewCap
Florent Alba/Nicolas Mérigeau
poxel@newcap.fr
+ 33 1 44 71 98 55

Investor relations / Media - EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Anca Alexandru
aalexandru@macbiocom.com
+ 49 89 2424 3494